Fig. 5.

Therapy with guadecitabine and AIT slows tumor growth and improves overall survival compared to either treatment alone. a 4 T1 tumor-bearing mice were either untreated or treated with guadecitabine on days 3–6, and AIT mice then received CYP and 25 million antigen-experienced lymphocytes on days 3 and 4, respectively. b Tumor progression was measured until humane endpoints were reached; dotted line indicates day statistical significance was determined by c area under the curve or d tumor area. e Survival curves depicting overall survival in each treatment group. Significance determined using ANOVA with Tukey’s multiple comparison test Error bars represent SEM. *:p value< 0.0332; **:p value< 0.0021; ***:p value< 0.0002; ****:p value< 0.00001